Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

CONCLUSION: κ.CART infusion is feasible and safe and can lead to complete clinical responses. TRIAL REGISTRATION: ClinicalTrials.gov NCT00881920. FUNDING: National Cancer Institute (NCI) grants 3P50CA126752 and 5P30CA125123 and Leukemia and Lymphoma Society (LLS) Specialized Centers of Research (SCOR) grant 7018. PMID: 27270177 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27270177?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - June 5, 2016 Category: Cancer & Oncology Authors: Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G Tags: J Clin Invest Source Type: research